Ayahuasca and ibogaine are not alternatives to each other. Both are used in healing contexts — for addiction, trauma, depression, and conditions that conventional treatment has not resolved. But they work through different mechanisms, produce experiences that do not resemble each other, and have different medical requirements. The most consequential one: ayahuasca contains MAOIs, and MAOIs are an absolute contraindication for ibogaine. That is not a preference to weigh. It is a hard pharmacological limit.
Ayahuasca contains DMT and beta-carboline MAOIs from Banisteriopsis caapi vine. Ibogaine is an alkaloid from the root bark of Tabernanthe iboga. They act on different receptor systems, produce different experiences, and require a clear separation window. The 2023 Stanford study found 88% reductions in PTSD symptoms at one month in 30 veterans given ibogaine. Vancouver, BC is the nearest legal destination for most North Americans seeking ibogaine.
What Ayahuasca Is and What Ibogaine Is
Ayahuasca is a brew traditionally prepared from Banisteriopsis caapi vine and Psychotria viridis leaves. The caapi vine contains beta-carboline alkaloids — harmine, harmaline, tetrahydroharmine — that act as monoamine oxidase inhibitors. The leaves contain DMT. Without the MAOIs, orally consumed DMT breaks down before it reaches the brain. The brew works because those two components arrive together. The active experience runs 4–6 hours. Purging is common, and is understood in most traditions as part of the process rather than a side effect.
Ibogaine is an alkaloid from the root bark of Tabernanthe iboga, a plant native to Central and West Africa used ceremonially in the Bwiti tradition for centuries. A full ceremony produces an active experience of 12–24 hours. The compound acts on mu-opioid receptors, inhibits the serotonin transporter, acts as an NMDA antagonist, and appears to trigger release of GDNF — a neurotrophic factor depleted in addiction-affected dopamine pathways. Noribogaine, the active metabolite, remains pharmacologically active for weeks after a single ceremony.
The 2023 Stanford study, published in Nature Medicine, found 88% reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month in 30 special operations veterans given ibogaine. That population had already tried conventional treatment without adequate results. The study has real methodological limitations — 30 veterans is not a definitive population, and there was no placebo arm — but the results are consistent with what practitioners have observed for years.
Research on ayahuasca for depression and trauma has been building for over a decade. A 2016 study in Frontiers in Pharmacology found significant reductions in depression and anxiety scores in patients with treatment-resistant conditions. The populations seeking both medicines overlap considerably — people for whom conventional treatment has not been sufficient.
How They Differ in Mechanism and Experience
Ayahuasca works primarily through DMT's action on 5-HT2A serotonin receptors. The experience is characterised by visual content — geometric patterns, symbolic imagery, what people often describe as encounters with presences. The emotional texture varies widely between participants and ceremonies. The content tends to be symbolic rather than literal. People encounter their past in metaphor more often than in direct memory replay.
Ibogaine is different in this specific way. The content is biographical rather than symbolic. People describe reviewing their own life in direct terms — specific memories, specific relationships, the pattern of decisions that produced their current situation — with something closer to clarity than the emotional charge those memories would normally carry. The experience is not expansive. It is confrontational and specific. Nausea is common. Ataxia — difficulty standing without support — is typical in the early hours. The physical experience is demanding in a way that surprises people regardless of what they have read beforehand. The active experience runs 12–24 hours, not 4–6.
The integration windows also differ. Ayahuasca produces elevated neuroplasticity through BDNF upregulation and 5-HT2A activity, but the window is shorter. Ibogaine produces a longer neuroplastic state through noribogaine — the active metabolite that sustains elevated BDNF for weeks to months after a single ceremony. This is part of why the integration period after ibogaine is longer and more consequential: the window in which new patterns are more accessible is genuinely different in duration, not just in the difficulty of the experience itself.
More on the ibogaine mechanism is in the post on what ibogaine does to the brain. More on the whole-plant experience is in the post on ayahuasca and iboga.
What They Address in Common
Both medicines are used for trauma, addiction, depression, and conditions where the source of the problem has not been adequately addressed by conventional treatment. The people who seek them often share something else: they have tried the standard approaches — medication, therapy, abstinence programmes — without adequate results. They are not naive about the difficulty of what they are attempting to change.
Both medicines also require the same thing after ceremony. The experience surfaces material. The weeks that follow determine what is done with it. Providers who end the programme at the ceremony are not providing treatment. They are providing the medicine. Those are not the same thing. Integration coaching — available at Transcend for $150–$300 CAD per session — is the part most directly responsible for whether the neuroplasticity window produces lasting change. The integration page explains what that work involves.
Can You Work With Both — and in What Order
Some people ask whether they should work with both ayahuasca and ibogaine, and in what sequence. The answer depends on what they are addressing and whether they meet the medical criteria for each — criteria that are not identical and must be assessed separately.
Some people who have worked with ayahuasca find it surfaces material they want to work with more directly. Ayahuasca shows things symbolically. Ibogaine tends to address the same territory in literal terms — the specific memories, the specific relational patterns. For some people, ayahuasca is preparation for ibogaine in the sense that it raises the questions ibogaine will then address directly.
Some people who have worked with ibogaine seek ayahuasca later, in a different window. The medicines are not competing. They address different layers of the same conditions through different mechanisms.
What does not work is attempting both within the same treatment window. The reason is not philosophical. It is pharmacological — and it applies to rapid sequencing too, not only to concurrent use.
The MAOI Rule — Why This Matters
Ayahuasca contains MAOIs. Ibogaine inhibits the serotonin transporter. Combining a serotonin transporter inhibitor with MAOIs creates conditions for serotonin syndrome — acute, potentially fatal accumulation of serotonin in the nervous system. This is the same mechanism that makes SSRIs an absolute contraindication for ibogaine, and the same reason MAOIs are contraindicated with SSRIs in standard prescribing practice.
The practical consequence: a full elimination window is required between ayahuasca use and ibogaine ceremony. The beta-carboline MAOIs in ayahuasca clear their acute pharmacological effect within 24–48 hours. But conservative practice — and most legitimate providers — require a minimum of two weeks between any ayahuasca ceremony and ibogaine administration. Some require four. This is not a suggestion. It is a hard medical boundary.
Some people reason that because they have used both at different times without incident, the risk is manageable. It is not. Serotonin syndrome can be severe and fatal. The absence of a prior adverse event reflects timing and dose, not the absence of underlying risk. The contraindication stands regardless of prior experience.
Every intake conversation at Transcend includes a direct question about recent ayahuasca use. It is a medical question with a pharmacological consequence — not a formality.
Who Should Not Consider Either Medicine
Some contraindications apply to both. Others are specific to each.
For ibogaine specifically: QT prolongation and significant cardiac arrhythmia are absolute contraindications — ibogaine extends the QT interval for the full active experience, and this is the mechanism behind cardiac deaths when providers skip the pre-ceremony EKG. Current SSRIs or SNRIs require a completed, physician-supervised taper before any ceremony date is confirmed. Lithium, methadone without a specific transition protocol, severe liver or kidney disease, active psychosis, and pregnancy are also absolute contraindications.
For ayahuasca specifically: Current SSRIs, SNRIs, and any MAOI-containing compound create serotonin syndrome risk. Most antipsychotics. Several cardiovascular medications interact with the beta-carboline alkaloids in the brew. Personal or first-degree family history of psychotic spectrum disorder is a significant risk factor.
For both: Someone in acute psychiatric crisis is not an appropriate candidate for either medicine at this time, regardless of how urgently they want access. Both medicines amplify what is present. Entering either in a state of acute destabilisation does not produce stabilisation.
The full contraindications for ibogaine are detailed in the post on ibogaine contraindications. The FAQ covers the most common questions about candidacy and medical screening.
Starting a Conversation
If you are considering ibogaine and have a recent history of ayahuasca use, include that information in your application. It is not a disqualifier — it is information that shapes the timeline and the intake conversation.
Iboga ceremony at Transcend in Vancouver, BC costs $2,000–$5,000 CAD. This covers an on-site medical professional throughout the 12–24 hour active experience, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and a 2–3 day supervised recovery period. 5-MeO-DMT ceremony — available separately or in sequence with iboga for appropriate candidates — costs $600–$1,500 CAD. Integration coaching is $150–$300 CAD per session.
Every application receives a personal response within 2–3 business days. No ceremony date is confirmed before medical screening establishes candidacy. The ceremony page covers what the programme involves from first contact through recovery. Or reach out directly: jake.nylund@gmail.com.
Frequently Asked Questions
Can you take ibogaine after ayahuasca?
Yes — but not immediately. A minimum of two weeks is required between ayahuasca use and ibogaine; four weeks is the more conservative and more commonly recommended window. Ayahuasca contains beta-carboline MAOIs; ibogaine inhibits the serotonin transporter. Combining them creates conditions for serotonin syndrome, which can be severe or fatal. The MAOIs in ayahuasca clear their acute effect within 24–48 hours, but the conservative window exists because the consequence of getting the timing wrong is serious. Include your ayahuasca history in your screening conversation.
What is the difference between ayahuasca and ibogaine?
Ayahuasca is a brew containing DMT and beta-carboline MAOIs. It produces a 4–6 hour experience characterised by visual, symbolic content — geometric patterns, imagery, what people describe as encounters with presences. Ibogaine is from Tabernanthe iboga root bark and produces a 12–24 hour experience characterised by biographical content — specific memories and relational patterns reviewed with unusual clarity. Different receptor systems, different experience quality, different duration, different integration requirements.
Which is stronger — ayahuasca or ibogaine?
The comparison does not hold cleanly. Ibogaine lasts 12–24 hours versus 4–6 for ayahuasca and is more physically demanding. The content of ibogaine tends toward directness and specificity; ayahuasca toward the symbolic and visionary. Some people who have worked with both describe ibogaine as more confrontational. Others find ayahuasca more emotionally intense. They are different medicines, not different intensities of the same one.
Can you combine ayahuasca and ibogaine in the same ceremony?
No. Ayahuasca contains MAOIs; ibogaine inhibits the serotonin transporter. Combining them creates conditions for serotonin syndrome, which can be fatal. This is not a preference to weigh — it is a hard pharmacological contraindication. No legitimate provider would administer them together or in rapid succession.
How long after ayahuasca can you do ibogaine?
A minimum of two weeks; four weeks is the more conservative and more commonly recommended window. The beta-carboline MAOIs in ayahuasca clear their acute pharmacological effect within 24–48 hours, but conservative providers require a longer window because the consequence of inadequate clearance — serotonin syndrome — is serious. Tell your provider exactly when your most recent ayahuasca ceremony occurred.
Who should not use ayahuasca or ibogaine?
Someone in acute psychiatric crisis is not an appropriate candidate for either medicine at this time. For ibogaine: QT prolongation, current SSRIs or SNRIs without a completed supervised taper, lithium, methadone, severe liver disease, and pregnancy are absolute contraindications. For ayahuasca: current SSRIs, SNRIs, MAOIs, and most antipsychotics create serotonin syndrome risk. Personal or first-degree family history of psychotic spectrum disorder is a serious risk factor for both.
Is ayahuasca legal in Canada?
DMT is scheduled under Canada's Controlled Drugs and Substances Act. Ayahuasca as a brew exists in a legally complex position — it is not explicitly scheduled as a brew, but DMT is the active compound. In practice, ayahuasca ceremonies in Canada operate in a legally uncertain environment. Ibogaine, by contrast, is not listed under the CDSA, which allows ibogaine providers to operate openly with full medical infrastructure — a meaningful distinction in safety terms.